Nuvigil
armodafinil
Treatment for NarcolepsyUpdate: Nuvigil Now FDA Approved - June 15, 2007
Cephalon Inc. Granted Composition of Matter Patent Covering Nuvigil
New Patent Protection Extends Until 2023
FRAZER, Pa., November 7, 2006 -- Cephalon, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,132,570 (the '570 patent) covering a novel polymorphic form of armodafinil, the active pharmaceutical ingredient in Nuvigil (armodafinil) Tablets, which is pending approval with the U.S. Food and Drug Administration (FDA). The issued patent will expire on Dec. 18, 2023, and specifically claims compositions of matter of the Form I polymorph of armodafinil, as well as pharmaceutical formulations and methods of manufacturing.
"Our scientists have discovered several novel polymorphs associated with armodafinil. Significantly, we believe polymorphic Form I is the most stable crystalline form of these, is present in the formulation that we expect to bring to market, and is very likely to be present in any other formulation of armodafinil that may be developed," said Dr. Jeffry Vaught, Executive Vice President and President of Research & Development. "We believe this patent will provide strong protection for Nuvigil."
John E. Osborn, Executive Vice President and General Counsel, said, "Our Provigil patent litigation settlements of the past year, and the associated licenses to certain intellectual property, do not grant any rights to this important patent. This new protection provides us with the confidence to continue to develop this market and expand our wakefulness franchise."
The company submitted a new drug application in 2005 seeking to market Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). The company received an approvable letter for Nuvigil earlier this year from the FDA, and a response from the agency is expected no later than Dec. 31, 2006.
Source: Cephalon, Inc.
Related Articles:
Cephalon Receives FDA Approval of Nuvigil for the Treatment of Excessive Sleepiness Associated with Three Disorders - June 18, 2007
Cephalon Provides Update Related to Nuvigil New Drug Application - April 2, 2007
Cephalon Receives Approvable Letter for Nuvigil - May 1, 2006
Cephalon Files New Drug Application for Nuvigil - March 31, 2005
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
